CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Ceftazidime-avibactamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04358991
NCT04358991N/ACompleted
CompareCT.gov

Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving Continuous Venovenous Hemodiafiltration

University of Pittsburgh·observational·Posted Apr 24, 2020·Updated Sep 29, 2020

In Brief

An observational study evaluating Ceftazidime-avibactam for Bacterial Infections. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections
CountriesUnited States
CollaboratorsAllergan

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 24, 2020
Enrollment StartJan 1, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 6.2 years ago

Interventions

Ceftazidime-avibactamdrug

collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.